Scynexis (SCYX) Net Cash Flow Growth (1y) (2014 - 2026)
Scynexis (SCYX) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -117.27% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -167.84% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -290.21% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 270.63% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -367.42% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -7.60% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 272.00% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - | -793.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -793.07% |
| Mar 31, 2026 | 269.20% |
| Dec 31, 2025 | 150.97% |
| Sep 30, 2025 | 35.99% |
| Jun 30, 2025 | 139.82% |
| Mar 31, 2025 | -736.10% |
| Dec 31, 2024 | -26.51% |
| Sep 30, 2024 | 119.71% |
| Jun 30, 2024 | -130.24% |
| Mar 31, 2024 | 107.58% |
| Dec 31, 2023 | 56.06% |
| Sep 30, 2023 | 72.26% |
| Jun 30, 2023 | 33.61% |
| Mar 31, 2023 | -103.81% |
| Dec 31, 2022 | -621.28% |
| Sep 30, 2022 | -304.09% |
| Jun 30, 2022 | 14.91% |
| Mar 31, 2022 | -800.39% |
| Dec 31, 2021 | -93.12% |
| Sep 30, 2021 | -173.71% |